[Development of neonatal Graves' disease--prediction, prevention and treatment].
It is well known that neonatal hyperthyroidism or neonatal Graves' disease is caused by trans-placental transfer of TSH receptor antibodies. The antibodies stimulate the thyroid gland in the fetal and neonatal stages, which induces hyperfunction of the thyroid gland and increased thyroid hormone production. In this paper, I would like to focus on four clinically interesting issues related neonatal hyperthyroidism. 1. High risk of mothers whose infants develop neonatal Graves' disease. 2. How to predict for development of neonatal Graves' disease. 3. How to prevent for development of neonatal Graves' disease. 4. How to treat the infants with Graves' disease. I also mention on the neonatal thyrotoxicosis and fetal hyperthyroidism.
Matsuura
Nobuo
N
Department of Early Childhood Education, Seitoku University.
D001323:Autoantibodies / Q000032:analysis / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D005260:Female; D005315:Fetal Diseases; D006111:Graves Disease / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000378:metabolism; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011237:Predictive Value of Tests; D011247:Pregnancy; D011248:Pregnancy Complications; D012306:Risk; D012307:Risk Factors; D013971:Thyrotoxicosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy
D001323:Autoantibodies; D015415:Biomarkers; D018828:Immunoglobulins, Thyroid-Stimulating; C094372:thyrotropin-binding inhibitory immunoglobulin